Currently set to Index
Currently set to Follow
ask age2b

Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX

By AGE2B team
May 12, 2021

Anthony P Carnicelli 1, Jie-Lena Sun 2, Brooke Alhanti 2, Magnus Bjursell 3, Shira Perl 4, Barbara Lytle 2, Matthew T Roe 5, Robert J Mentz 5

Main idea: Serum uric acid is an important marker of comorbidities and functional status in patients with heart failure with preserved ejection fraction. Clinical trials of serum uric acid-lowering therapies in patients with heart failure with preserved ejection fraction are promising.


Purpose: We aimed to 1) describe characteristics of patients with heart failure with preserved ejection fraction (HFpEF) enrolled in RELAX stratified by normal or elevated baseline serum uric acid (sUA) level; 2) evaluate the association between sUA level and surrogate clinical measures; and 3) assess associations between changes in sUA level over time and changes in surrogate clinical measures.

Methods: We analyzed 212 patients with HFpEF and normal or elevated sUA measurements from the RELAX trial. Variables examined included clinical characteristics, cardiopulmonary exercise testing, 6-minute walk testing, quality of life, echocardiography, and serum biomarker testing.

Results: The prevalence of elevated baseline sUA was 68.9%. Patients with elevated sUA had more baseline comorbidities and poorer functional status on cardiopulmonary exercise testing than those without. Higher sUA levels were also associated with worsening peak VO2, 6-minute walk testing, and left ventricular mass.

Source NIH

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.